• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    3/11/21 11:12:53 AM ET
    $ZYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZYNE alert in real time by email
    SC 13G/A 1 ea137477-13ga6etf_zynerba.htm AMENDMENT NO. 6 TO SCHEDULE 13G

     

      

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 6)*

     

    Zynerba Pharmaceuticals Inc

     

    (Name of Issuer)

     

    Common Stock, $0.001 Par Value Per Share

     

    (Title of Class of Securities)

     

    98986X109

     

    (CUSIP Number)

     

    March 9, 2021

     

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☒ Rule 13d-1(b)

     

    ☐ Rule 13d-1(c)

     

    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    SCHEDULE 13G

     

     CUSIP No. 98986X109

     

    1 Names of Reporting Persons
    ETF Managers Group LLC
    2 Check the appropriate box if a member of a Group (see instructions)
    (a)  ☐
    (b)  ☒ See Item of attached schedule
    3

    Sec Use Only

     

    4 Citizenship or Place of Organization
    Delaware
    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting Person
    With:
    5 Sole Voting Power
    1,910,194
    6 Shared Voting Power
     
    7 Sole Dispositive Power
    1,910,194
    8 Shared Dispositive Power
     
    9 Aggregate Amount Beneficially Owned by Each Reporting Person
    1,910,194
    10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
    ☐
    11 Percent of class represented by amount in row (9)
    4.63%
    12 Type of Reporting Person (See Instructions)
    IA

     

    Page 2 of 5

     

      

    Item 1.

     

    (a)Name of Issuer: Zynerba Pharmaceuticals Inc
    (b)Address of Issuer’s Principal Executive Offices: 80 W. Lancaster Avenue, Suite 300, Devon, PA 19333

     

    Item 2.

     

    (a)Name of Person Filing: ETF Managers Group LLC

     

    (b)Address of Principal Business Office or, if None, Residence:

     

    ETF Managers Group LLC - 30 Maple Street, Suite 2, Summit, New Jersey 07091

     

    (c)Citizenship: ETF Managers Group LLC – Delaware

     

    (d)Title and Class of Securities: Common Stock

     

    (e)CUSIP No.: 98986X109

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ☐Broker or dealer registered under Section 15 of the Act;
        
    (b) ☐Bank as defined in Section 3(a)(6) of the Act;
         
    (c) ☐Insurance company as defined in Section 3(a)(19) of the Act;
         
    (d) ☐Investment company registered under Section 8 of the Investment Company Act of 1940;
         
    (e) ☒An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
         
    (f) ☐An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
         
    (g) ☐A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
         
    (h) ☐A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ☐A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
         
    (j) ☐A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
         
    (k) ☐Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Page 3 of 5

     

     

    Item 4.Ownership

     

    (a)Amount Beneficially Owned: 1,910,194

     

    (b)Percent of Class: 4.63%

     

    (c)Number of shares as to which such person(s) has:

     

    (i)Sole power to vote or to direct the vote: 1,910,194

     

    (ii)Shared power to vote or to direct the vote:

     

    (iii)Sole power to dispose or to direct the disposition of: 1,910,194

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

     

    Item 6.Ownership of more than Five Percent on Behalf of Another Person.

     

     Not Applicable

     

    Item 7.Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

     

    Not Applicable

     

    Item 8.Identification and classification of members of the group.

     

    Not Applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable

     

    Item 10.Certifications.

     

    By signing below, we certify that, to the best of our knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Page 4 of 5

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of our knowledge and belief, we certify that the information set forth in this statement is true, complete and correct.

     

    Dated: March 11, 2021  
       
    /s/ Reshma A. Tanczos  

    Name/Title: Reshma A. Tanczos,

    Chief Compliance Officer,

    ETF Managers Group LLC

     

     

     

     

    Page 5 of 5

     

     

    Get the next $ZYNE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZYNE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ZYNE
    SEC Filings

    See more
    • SEC Form 15-12G filed by Zynerba Pharmaceuticals Inc.

      15-12G - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)

      10/19/23 4:48:36 PM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Zynerba Pharmaceuticals Inc.

      EFFECT - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)

      10/12/23 12:15:05 AM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POS AM filed by Zynerba Pharmaceuticals Inc.

      POS AM - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)

      10/11/23 9:27:41 AM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYNE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE

      New product in development diversifies portfolio to drive long-term growth  Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders with high unmet medical needs Zygel™ in pivotal Phase 3 trial for Fragile X syndrome and has completed Phase 2 proof-of-concept study in 22q11.2 deletion syndrome PLYMOUTH MEETING, Pa., Oct. 11, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it has completed its acquisition of Zynerba Pharmaceuticals, Inc. ("Zynerba") (NASDAQ:ZYNE).

      10/11/23 8:00:00 AM ET
      $HRMY
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions

      DEVON, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today reminds all stockholders, including individual stockholders, to promptly tender their shares into the tender offer (the "Offer") by Harmony Biosciences Holdings, Inc. ("Harmony") and its wholly owned subsidiary, Xylophone Acquisition Corp. ("Purchaser"), to purchase all outstanding shares of Zynerba common stock. The Zynerba Board of Directors unanimously recommends that Zynerba stockholders tender their shares pursuant to the Offer. Key Information to Know Tender Deadl

      10/4/23 4:05:00 PM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023

      DEVON, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today released the following letter to stockholders concerning the pending tender offer by Harmony Biosciences Holdings, Inc. ("Harmony"). Fellow Zynerba Pharmaceuticals Stockholders, We urge you to promptly tender your shares in response to the pending tender offer (the "Offer") by Harmony and its wholly owned subsidiary, Xylophone Acquisition Corp. ("Purchaser"). As previously disclosed, the Offer is to purchase all of the issued and outstanding shares of the co

      9/29/23 9:00:00 AM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYNE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Jones Kenneth T was granted 30,000 shares, closing all direct ownership in the company (SEC Form 4)

      4 - Zynerba Pharmaceuticals, Inc. (0001621443) (Issuer)

      10/11/23 10:17:14 AM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stephenson Pamela closing all direct ownership in the company (SEC Form 4)

      4 - Zynerba Pharmaceuticals, Inc. (0001621443) (Issuer)

      10/11/23 10:12:57 AM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fickenscher James E was granted 170,000 shares, closing all direct ownership in the company (SEC Form 4)

      4 - Zynerba Pharmaceuticals, Inc. (0001621443) (Issuer)

      10/11/23 10:12:34 AM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYNE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Zynerba Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Zynerba Pharmaceuticals, Inc. (0001621443) (Subject)

      2/8/24 7:22:51 PM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Zynerba Pharmaceuticals Inc.

      SC 13G - Zynerba Pharmaceuticals, Inc. (0001621443) (Subject)

      9/5/23 4:39:51 PM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Zynerba Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Zynerba Pharmaceuticals, Inc. (0001621443) (Subject)

      2/14/22 3:52:48 PM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYNE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital reiterated coverage on Zynerba Pharmaceuticals with a new price target

      Roth Capital reiterated coverage of Zynerba Pharmaceuticals with a rating of Buy and set a new price target of $7.25 from $8.00 previously

      3/10/21 4:21:24 PM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity resumed coverage on Zynerba Pharmaceuticals with a new price target

      Canaccord Genuity resumed coverage of Zynerba Pharmaceuticals with a rating of Buy and set a new price target of $18.00

      2/5/21 4:18:35 AM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYNE
    Leadership Updates

    Live Leadership Updates

    See more

    $ZYNE
    Financials

    Live finance-specific insights

    See more
    • Zynerba Pharmaceuticals Announces Planned Retirement of Suzanne Hanlon and Appoints Albert P. Parker as Chief Legal Officer

      DEVON, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the appointment of Albert P. Parker, an accomplished industry executive with over 25 years of pharmaceutical, biotech and healthcare experience, as Chief Legal Officer and Corporate Secretary. He will assume the duties of Suzanne Hanlon who will retire from her position at the end of February 2022. "We are excited to have Al join our senior leadership team. He is an experienced legal and business executive who brings significant strategic and hands-o

      2/15/22 7:00:00 AM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunome Provides Organizational Update: Appoints Richard Baron to its Board of Directors and Sandra Stoneman as Chief Legal Officer and Corporate Secretary

      EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, with a focus on oncology and infectious diseases including COVID-19, today announced the recent appointments of Richard Baron to Immunome’s Board of Directors and as Audit Committee Chair, and Sandra Stoneman, Esq. as Chief Legal Officer and Corporate Secretary. The company also today announced that its President and Chief Executive Officer, Purnanand Sarma, Ph.D. is the recipient of TiE Boston’s 2020 Lifetime Achievement Award. The award recognizes individuals who have made invaluab

      12/10/20 8:00:00 AM ET
      $GMED
      $PUMP
      $ZYNE
      Medical/Dental Instruments
      Health Care
      Oilfield Services/Equipment
      Energy
    • HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE

      New product in development diversifies portfolio to drive long-term growth  Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders with high unmet medical needs Zygel™ in pivotal Phase 3 trial for Fragile X syndrome and has completed Phase 2 proof-of-concept study in 22q11.2 deletion syndrome PLYMOUTH MEETING, Pa., Oct. 11, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it has completed its acquisition of Zynerba Pharmaceuticals, Inc. ("Zynerba") (NASDAQ:ZYNE).

      10/11/23 8:00:00 AM ET
      $HRMY
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.

      PLYMOUTH MEETING, Pa. and DEVON, Pa., Aug. 14, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. ("Zynerba") (NASDAQ:ZYNE), a leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, including Fragile X syndrome (FXS). Under the terms of the definitive agreement, Harmony

      8/14/23 7:30:00 AM ET
      $HRMY
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome

      – The INSPIRE trial achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments – – Safety data reinforce excellent tolerability profile of Zygel – – Company will focus resources on FXS and 22q development – – Cash runway extended through the end of 2023 / early 2024 – – Zynerba to host conference call and webcast tomorrow, June 22, 2022 at 9:00 a.m. ET – DEVON, Pa., June 21, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced positive top line results from the explorat

      6/21/22 8:05:00 PM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care